Big Pharma More Willing To Cooperate On Neglected Disease Research But Funding Models Still Unclear
This article was originally published in PharmAsia News
Executive Summary
HONG KONG - Debate over how best to fund research and development of neglected diseases may be reshaped by changing patterns of cooperation among Big Pharma and non-industry groups
You may also be interested in...
BIOTEC, Novartis Extend Partnership To Mine Thai Biodiversity For Drug Discovery
Novartis exchanges training for access to Thailand’s native natural compounds for drug discovery.
Pharma Joins Forces With WHO, Global Governments In Unprecedented Effort To Control Neglected Tropical Diseases
Big Pharma join hands with WHO, global governments and foundations in unprecedented effort to wipe out neglected tropical diseases.
Novartis Head of Corporate Research And Chairman, Novartis Institute For Tropical Diseases, Paul Herrling On The Need For Government Funding For Neglected Diseases: An Interview With PharmAsia News
Paul Herrling, Head of Corporate Research at Novartis and Chairman of the Novartis Institute For Tropical Diseases, Singapore spends a week each month in Singapore and for the rest he fulfills his other global commitments. Herrling sat down with PharmAsia News in Singapore to discuss research initiatives for neglected diseases and controversies revolving around his proposal for a fund to research neglected diseases by multiple governments.